The incidence of multiple primary malignant neoplasms increases with age. An unforeseen finding is the high number of prostate and bladder cancers pairs. Of prostate and bladder cancers pair as first primary and second primary cancers and vice versa, we investigated the differences in clinicopathological features between synchronous and metachronous primary carcinomas of the bladder and prostate.
INTRODUCTION
The proposed criteria of multiple primary malignant neoplasms (MPMs) are histologically confirmed histologically malignancy of both tumors, anatomical distinctiveness of the tumors, and the second tumor not being a recurrence or metastasis of the first cancer. 1 Further classification based on the timing of an each malignancy has been dichotomized as MPMs being synchronous or metachronous malignancies. 2 The phenomenon of MPMs is increasingly being discussed in the literature due to the increased survival time of cancer patients after treatment and because of advances in diagnostic methods.
Multiple neoplasms have been estimated to affect about 10% of all cancer patients. [3] [4] [5] MPMs often occur in the bladder and prostate. Two primary carcinomas can coexist at the time of diagnosis, or develop consequently, sometimes years after resection of the first primary.
Bladder cancer is the second most prevalent urologic cancer after prostate cancer. 6 It may occur alone or associated with other cancers of the urogenital tract, particularly the prostate. Several authors report a surprisingly close association between bladder and prostate cancer. [7] [8] [9] However most study focused on prostate cancer which was be incidentally found after radical cystoprostatectomy (RCP).
The purpose of the present study was to determine the differences in clinicopathological features between synchronous and metachronous primary carcinomas of the bladder and prostate.
MATERIALS AND METHODS

Subjects
This study protocol was reviewed and approved by the 
Tumor Classification
We defined synchronous and metachronous cancer based on
Moertel's definition. 10 Synchronous cancers were defined as those occurring within 6 months of the first primary cancer, while metachrous cancers were defined as those occurring more than 6 months later. months in group I, II, and III, respectively, which showed a significant difference (p=0.007).
Statistical Analyses
RESULTS
Mean PSA was 2.7±1.1, 3.5±2.2, and 2.4±0.9 ng/dL in groups I, II, and III, which showed no significant difference (p=0.200). The number of patients who were current smokers or ex-smokers was 11, 0, and 7 in groups I, II, III (p=0.197).
There were no statistical differences of bladder cancer stage, grade, and multifocality between groups. However, group III showed a lower prostate cancer stage (NCCN anatomic stage; p=0.009) and had a lower risk of prostate cancer (p=0.025). 
DISCUSSION
In this study, synchronous malignancies accounted for nearly 55% of the second primary malignancies and then bladder cancer with metachronous prostate cancer is the second most common. In an analysis of the Minneapolis Veterans Affairs tumor registry, prostate cancer was one of the most common cancers seen in a sample of synchronous and metachronous malignancies. 7 During the period of this prior study, prostate cancer comprised almost 34% of all primary cancer diagnoses and 16% of all secondary cancer diagnoses. There were also high rates of primary (13.4% of cases) and secondary malignancies (9.3%) in bladder and ureter cancers. An unforeseen finding was the high number of prostate and bladder cancers pairs. Of prostate and bladder cancers pair as first primary and second primary cancers and vice versa, they made up 12% of the multiple primary malignant tumor cohorts. 7 Montie et al. 8 and Abba et al. 9 described high rates of incidental prostate cancers found as a result of cystoprostatectomy. Due to the high number of these synchronous malignancies occurring in our cohort, there was also the possibility that shared molecular pathways of carcinogenesis may exist in these 2 histologically unique cancers. Further investigation into this hypothesis is warranted. Old age is a common risk factor for bladder and prostate cancer, because prostate and bladder cancers occur more often in elderly patients as the incidence of malignancies increases with age. 12 In addition, the combination of prostate and bladder cancer might be due to their common embryological origin with similarities at the molecular level. 9, 11 Indeed, the involvement of 3 oncogenes and deletion of 3 gene suppressors (Rb, p53, and 23 nm) have been described as possible causes for this association. 13 Also, the prostate stem cell antigen is overexpressed in the most transitional cell carcinomas and more genotypes of rapid N-acetyltransferase was observed in patients with these 2 cancers. This enzyme, known for its activation of carcinogenic amines, is higher in patients with double cancers than in control groups. 13, 14 Prostate and bladder cancers may be secondary to urinary stasis. 15 The incidence of bladder cancer in the diverticulum is estimated at 10%. 16 Kirby et al. 15 observed a reflux of urine with prostatic intraurinary stasis in the peripheral zone of the prostate. The authors concluded that carcinogens identified in the bladder may have an effect on the development of prostate cancer. Chronic inflammation and a common carcinogen in the bladder and prostate may be responsible for the concurrent cancers. [15] [16] [17] [18] It remains true that the incidence of prostate cancer in a series of radical cystoprostatectomies with unscreened and unselected patients could be nearly 50%. 19, 20 In this study, we exclude patients with the incidentally detected prostate cancer.
However, synchronous prostate cancer or bladder cancer detected within 6 months accounted for nearly 55% of the second primary malignancies and then bladder cancer with metachronous prostate cancer is second most common.
There were more group III patients (metachronous prostate cancer) than group II patients (metachronous bladder cancer).
This may be due to the fact that prostate cancer screening is routinely done in elderly patients. Indeed, the incidence of prostate cancer in patients with bladder cancer is 18 times higher than in the general population. However, the incidence of bladder cancer in patients with prostate cancer is also 19 times higher than in the general population. This risk varies from 2.8% to 70%. 8, 11, 21, 22 These phenomena may be due to incidental findings resulting in a second malignancy diagnosis.
For example, most patients with prostate cancers will be checked by imaging studies to determine cancer stage and their surgical candidacy. This imaging study may result in unintentional screening test that diagnoses a second primary cancer. Metachronous prostate cancer after prostate-sparing radical cystectomy can be diagnosed during follow-up as well, but this is unlikely to be the main cause of mortality. Prostate cancer identified during follow-up after prostate-sparing radical cystectomy can be approached the same way as under 'noncystectomy' circumstances.
One limitation of our study is the retrospective design that leads to selection bias, firstly. Secondly, our study consisted of only 53 patients, and so cannot represent general population.
In addition, group 2 had only 8 patients, which limits accuracy.
Lastly, despite lower NCCN risk and lower NCCN stage of prostate cancer in group III, there was no significant difference in cause of death between 3 groups. This result might be due to a longer follow-up period in group III than other groups. So, investigation by long-term follow-up in groups I and II and multiple center study could be helpful to understand the properties of synchronous and metachronous bladder and prostate carcinomas.
CONCLUSIONS
We found that synchronous primary malignancies of prostate and bladder are more common than metachronous bladder or prostate malignancies. Bladder tumor showed no differences in the characteristics and clinicopathological features between synchronous and metachronous primary carcinomas. However, metachronous prostate cancer showed better clinicopathological features of prostate cancer. It is important for clinicians to counselling and decision making in considering of prostate-sparing radical cystectomy.
